Biofarm (stock symbol BIO), one of the most important drug manufacturers in Romania, announces increased production of paracetamol-based medicines for the treatment of fever and pain in children to meet increased market demand.
“We are in the middle of the children’s respiratory season and paracetamol-based medicines are very hard to find or are missing from pharmacies. Therefore, we have mobilised and decided to significantly increase production of Bioflu Baby, a paracetamol-based syrup for treating fever and pain in children. Biofarm has an extensive portfolio of products for children’s colds and flu, and our two manufacturing facilities have the capacity to adapt quickly to any market need,” said Cătălin Vicol, Biofarm’s CEO.
Biofarm has always focused on aligning itself with market requirements and patient needs, being a company always oriented towards innovation and facilitating access to modern treatment solutions.
In the first ten months of 2022, Biofarm ranked 3rd in the Consumer Healthcare (CHC) segment in terms of number of units sold. The Cold & Flu therapeutic area saw the highest growth in the Consumer Healthcare (CHC) category, with products such as Bioflu, Carmol, Bixtonim Xylo and Septosol recording double-digit growth.
Biofarm currently has two drug factories in Bucharest and a product testing and development unit, and its portfolio of over 200 products covers the most important therapeutic areas of the Consumer Healthcare division (digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system).
With more than 20 representative brands, Biofarm is the market leader in terms of volumes in the reference categories of nine of its brands: Colebil, Triferment, Carbocit, Sennalax, Bixtonim, Carmol, Biofen, Nervocalmin and Cavit.